Nupro deleting OsteofleX supplement swelling, stiffness treatment claims at FDA's request.
This article was originally published in The Tan Sheet
Executive Summary
NUPRO DELETING OSTEOFLEX SWELLING AND STIFFNESS TREATMENT CLAIMS after receiving a Jan. 21 "courtesy letter" from FDA's Office of Special Nutritionals stating that certain claims for the dietary supplement are unapproved drug claims subject to additional regulation. "The statements that you are making for this product suggest...it is intended to treat, prevent or mitigate degenerative and/or other joint diseases and conditions and to treat muscle or mitigate muscle conditions," the letter states. Companies are required to file their structure/function claims with FDA within 30 days of marketing a dietary supplement product under the Dietary Supplement Health & Education Act.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning